Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Corautus Genetics |
---|---|
Information provided by: | Corautus Genetics |
ClinicalTrials.gov Identifier: | NCT00090714 |
The purpose of this study is to determine the optimum effective dose of recombinant plasmid DNA [pVGI.1(VEGF2)] gene therapy administered using an experimental cardiac direct injection catheter (Stiletto™) system needed to benefit patients with severe Angina Pectoris.
Condition | Intervention | Phase |
---|---|---|
Angina Pectoris |
Gene Transfer: pVGI.1(VEGF2) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | VEGF2-CAD-CL-007, NIH RAC # 0301-567 |
Study First Received: | September 2, 2004 |
Last Updated: | April 18, 2006 |
ClinicalTrials.gov Identifier: | NCT00090714 |
Health Authority: | United States: Food and Drug Administration |
DNA Circular Gene Therapy |
Signs and Symptoms Heart Diseases Myocardial Ischemia Vascular Diseases |
Angina Pectoris Pain Ischemia Chest Pain |
Cardiovascular Diseases |